Swiss biopharmaceutical company AC Immune will conduct a clinical trial in the second half of 2018 to evaluate the viability of a new PET tracer for Parkinson's disease.
The study will examine the PET tracer's selectivity for aggregates of alpha-synuclein, a key target in Parkinson's, and thus its capacity to serve as an imaging biomarker for the disease, according to AC Immune. The company is presenting its current research on the topic at the AAT-AD/PDTM 2018 focus meeting in Turin, Italy.
AC Immune has been collaborating with biotechnology firm Biogen on this project, which is being funded by the Michael J. Fox Foundation for Parkinson's Research.
